NO973026L - Nye monoklonale antistoffer med virksom inhibitorisk aktivitet mot type II-fosfolipase A2 og proteiner omfattende en del derav - Google Patents

Nye monoklonale antistoffer med virksom inhibitorisk aktivitet mot type II-fosfolipase A2 og proteiner omfattende en del derav

Info

Publication number
NO973026L
NO973026L NO973026A NO973026A NO973026L NO 973026 L NO973026 L NO 973026L NO 973026 A NO973026 A NO 973026A NO 973026 A NO973026 A NO 973026A NO 973026 L NO973026 L NO 973026L
Authority
NO
Norway
Prior art keywords
phospholipase
type
proteins
monoclonal antibodies
inhibitory activity
Prior art date
Application number
NO973026A
Other languages
English (en)
Other versions
NO973026D0 (no
Inventor
Yasushi Kawauchi
Jun Takasaki
Tomoe Yasunaga
Yasuhiko Masuho
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of NO973026D0 publication Critical patent/NO973026D0/no
Publication of NO973026L publication Critical patent/NO973026L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Nytt monoklonalt antistoff som inhiberer aktiviteten av type Il-fos- folipase A2. Antistoffet inhiberer ak- tiviteten til human type Il-fosfolipase A2, apetype Il-fosfolipase A2 og/eller musetype Il-fosfolipase A2, noe som ikke bare gjør denne klinisk anvendbar, men også anvendbar til dette ved prekliniske tester med anvendelse av ape eller mus. Antistoffet, som har en fullstendig ny karakteristikk med hensyn til frigjøring av type Il-fosfolipase A2 bundet til cellemembran, ser ut til sterkt å hemme type Il-fosfolipase A2-aktiviten via en ny mekanisme. Et protein inneholdende det monoklonale antistoff eller en del av dette er anvendbart i form av et legemiddel mot hjerteinfarkt, hjernein- farkt etc, hvorved type Il-fosfolipase A2 deltar.
NO973026A 1994-12-29 1997-06-27 Nye monoklonale antistoffer med virksom inhibitorisk aktivitet mot type II-fosfolipase A2 og proteiner omfattende en del derav NO973026L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34000694 1994-12-29
PCT/JP1995/002714 WO1996020959A1 (fr) 1994-12-29 1995-12-27 Nouvel anticorps monoclonal ayant un effet inhibiteur sur la phospholipase a2 de type ii, et proteine contenant une partie de cet anticorps

Publications (2)

Publication Number Publication Date
NO973026D0 NO973026D0 (no) 1997-06-27
NO973026L true NO973026L (no) 1997-08-29

Family

ID=18332850

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973026A NO973026L (no) 1994-12-29 1997-06-27 Nye monoklonale antistoffer med virksom inhibitorisk aktivitet mot type II-fosfolipase A2 og proteiner omfattende en del derav

Country Status (11)

Country Link
EP (1) EP0799836A1 (no)
KR (1) KR970707162A (no)
CN (1) CN1171792A (no)
AU (1) AU4355496A (no)
CA (1) CA2204731A1 (no)
FI (1) FI972754A (no)
HU (1) HUT77041A (no)
NO (1) NO973026L (no)
NZ (1) NZ298145A (no)
PL (1) PL321161A1 (no)
WO (1) WO1996020959A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049427A1 (fr) * 1996-06-27 1997-12-31 Yamanouchi Pharmaceutical Co., Ltd. Medicament permettant d'attenuer les problemes renaux
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
ID27153A (id) * 1998-05-01 2001-03-08 Lilly Co Eli Senyawa inhibitor spla2 untuk mengobati penyakit
EP1265607A2 (en) * 2000-03-09 2002-12-18 Eli Lilly And Company METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
DK1673397T3 (da) 2003-07-02 2011-03-07 Univ Genova Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
JP2007505862A (ja) 2003-09-22 2007-03-15 バイオスペシフィク ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ｓＰＬＡ２の効果の失効方法
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
NZ574215A (en) * 2006-07-18 2012-07-27 Sanofi Aventis Antagonist antibody against epha2 for the treatment of cancer
EP2581388A1 (en) * 2011-10-14 2013-04-17 Centre National de la Recherche Scientifique (CNRS) Anti-sPLA2-V antibodies and uses thereof
US10000572B2 (en) * 2013-08-01 2018-06-19 Université Catholique de Louvain Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
WO2016073747A1 (en) 2014-11-06 2016-05-12 The Trustees Of The University Of Pennsylvania Atomic description of immune complex that causes heparin-induced thrombocytopenia
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
CN108840918B (zh) * 2018-06-14 2021-07-23 浙江农林大学 Pla2抑制剂编码基因的克隆方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0717680B2 (ja) * 1987-04-15 1995-03-01 塩野義製薬株式会社 ヒト▲膵▼ホスホリパ−ゼａ▲下２▼に対するモノクロ−ナル抗体、その製造法、該モノクロ−ナル抗体産生ハイブリド−マおよび該モノクロ−ナル抗体を用いたヒト▲膵▼ホスホリパ−ゼａ▲下２▼の測定方法
JP2984029B2 (ja) * 1990-05-30 1999-11-29 塩野義製薬株式会社 膜型ホスホリパーゼａ▲下２▼を認識するモノクローナル抗体および膜型ホスホリパーゼａ▲下２▼の免疫測定法
JPH07109300A (ja) * 1993-10-13 1995-04-25 Teijin Ltd ヒトｉｉ型ホスホリパーゼａ２と結合する抗体

Also Published As

Publication number Publication date
NO973026D0 (no) 1997-06-27
AU4355496A (en) 1996-07-24
PL321161A1 (en) 1997-11-24
FI972754A0 (fi) 1997-06-26
FI972754A (fi) 1997-06-26
NZ298145A (en) 1998-08-26
WO1996020959A1 (fr) 1996-07-11
CN1171792A (zh) 1998-01-28
EP0799836A1 (en) 1997-10-08
KR970707162A (ko) 1997-12-01
MX9704879A (es) 1997-11-29
HUT77041A (hu) 1998-03-02
CA2204731A1 (en) 1996-07-11

Similar Documents

Publication Publication Date Title
NO973026L (no) Nye monoklonale antistoffer med virksom inhibitorisk aktivitet mot type II-fosfolipase A2 og proteiner omfattende en del derav
Cianciolo et al. Monocyte responsiveness to chemotactic stimuli is a property of a subpopulation of cells that can respond to multiple chemoattractants
Chan et al. An NMDA receptor signaling complex with protein phosphatase 2A
Nash et al. Anergy in active pulmonary tuberculosis: a comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses
Rose Excretion of xanthurenic acid in the urine of women taking progestogen-oestrogen preparations
Flurkey et al. Memory T lymphocyte hyporesponsiveness to non‐cognate stimuli: a key factor in age‐related immunodeficiency
Shiu et al. B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection
ATE435282T1 (de) Menschliche hämatopoietische stamm und vorläuferzellantigen und methoden zu dessen verwendung
Raspé et al. Identification of the thyroid Na+/I− cotransporter as a potential autoantigen in thyroid autoimmune disease
Obispo et al. The main allergen of Olea europaea (Ole e I) is also present in other species of the Oleaceae family
Hoffmann et al. Determination of the allergenic activity of birch pollen and apple prick test solutions by measurement of β‐hexosaminidase release from RBL‐2H3 cells. Comparison with classical methods in allergen standardization
ES2181674T3 (es) Dominios de union en las proteinas notch y delta.
YING et al. High‐affinity immunoglobulin E receptor (FcεRI)‐bearing eosinophils, mast cells, macrophages and Langerhans’ cells in allergen‐induced late‐phase cutaneous reactions in atopic subjects
Cadillo-Chavez et al. Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay
Afar et al. Activated lymphocyte subsets in adult periodontitis
Burger et al. Human transfer factor: Effects on lymphocyte transformation
Schweneker et al. HIV-induced changes in T cell signaling pathways
Hindle et al. Multidimensional flow cytometry reveals novel platelet subpopulations in response to prostacyclin
Lebedev et al. Peripheral blood lymphocytes immunophenotype and serum concentration of soluble HLA class I in burn patients
Sayed et al. Effect of major burns on early and late activating markers of peripheral blood T lymphocytes
Ripoll et al. T cells responding to Trypanosoma cruzi detected by membrane TNF‐α and CD154 in chagasic patients
Hamdi et al. Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome
Aarli Binding of γ-globulin fragments to muscle tissue
Milia et al. Gene activating and proapoptotic potential are independent properties of different CD4 epitopes
Riggio et al. Alpha-2-hyperglobulinaemia as a humoral indicator of the homograft reaction